| Code | Display |
| cc |
cc |
| dd |
dddd |
| aa |
aa |
| bb |
bb |
| ff |
ff |
| 382691000210103 |
CNS nerve primary |
| 382541000210108 |
Endocrine and/or neuroendocrine tumour (NET) primary |
| 390881000210102 |
Eye and/or orbit primary |
| 382551000210106 |
Neuroendocrine tumour gastroenteropancreatic (GEP-NET) primary |
| 382561000210109 |
Neuroendocrine tumour non-gastroenteropancreatic (non-GEP NET) primary |
| 390901000210104 |
Eyelid primary |
| 390801000210106 |
Colorectal neuroendocrine tumour (NET) primary |
| 390811000210108 |
Hepatic neuroendocrine tumour (NET) primary |
| 390821000210103 |
Urinary system neuroendocrine tumour (NET) primary |
| 390831000210101 |
Male genital neuroendocrine tumour (NET) primary |
| 390841000210109 |
Gynaecological neuroendocrine tumour (NET) primary |
| 390851000210107 |
Breast neuroendocrine tumour (NET) primary |
| 390861000210105 |
Head and neck neuroendocrine tumour (NET) primary |
| 390871000210104 |
CNS neuroendocrine tumour (NET) primary |
| 392081000210108 |
B-cell lymphoid proliferation |
| 392101000210103 |
T/ NK-cell lymphoid proliferation |
| 392031000210109 |
Aggressive B cell lymphoma |
| 392141000210100 |
Mature T/NK-cell lymphoid proliferation |
| 392121000210106 |
T-cell lymphoid proliferation |
| 390991000210105 |
Pituitary neuroendocrine tumour (PitNET) primary |
| 392071000210106 |
Plasmacytoid dendritic cell neoplasm |
| 392161000210104 |
Mature T/NK-cell leukaemia |
| 392201000210106 |
Primary cutaneous T cell lymphoproliferative disorder |
| 392211000210108 |
Intestinal T/NK-cell lymphoid proliferation |
| 392221000210103 |
EBV-positive T/NK-cell lymphoid proliferation |
| 92081000210108 |
Other B-cell lymphoid proliferation |
| 394231000210105 |
Nipple-areolar complex |
| 382491000210100 |
NGS - Next-generaton sequencing |
| gg |
gg |
| hh |
hh |
| 398111000210103 |
Appendicular skeleton primary |
| 398121000210108 |
Thoracic bone primary |
| 398131000210105 |
Skin soft tissue primary |
| 398141000210102 |
Head and neck soft tissue primary |
| 398161000210101 |
Extremity soft tissue primary |
| 398201000210108 |
Abdomen and/or pelvis soft tissue primary |
| 398231000210103 |
Retroperitoneal soft tissue primary |
| 398241000210106 |
CNS soft tissue primary |
| 398251000210109 |
Eye and/or orbit soft tissue primary |
| 448031000210108 |
Oral cavity and mobile tongue primary |
| 448051000210102 |
Nasal cavity and paranasal sinus primary |
| 448061000210104 |
Ear primary |
| 448071000210105 |
Pharynx, larynx and trachea primary |
| 448101000210102 |
Small intestine ileum and jejunum primary |
| 448081000210107 |
Parapharyngeal space primary |
| 448091000210109 |
Unknown primary tumour of head and neck |
| 392611000210105 |
BR Metastatic - cARBOplatin [2 AUC] and gemcitabine |
| 392601000210108 |
BR Metastatic - ribociclib |
| 392591000210103 |
LEU - GMALL T-LBL 1/2004 HDMTX/ASP [55 years and under] |
| 392581000210100 |
LEU - GMALL T-LBL 1/2004 Consolidation [55 years and under] |
| 392571000210102 |
LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [55 years and under] |
| 392561000210108 |
LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under] |
| 392551000210105 |
LEU - GMALL T-LBL 1/2004 triple prophylaxis |
| 392541000210107 |
LEU - GMALL T-LBL 1/2004 CYCLO/ARAC |
| 392531000210104 |
LEU - GMALL T-LBL 1/2004 VM26/ARAC |
| 392521000210101 |
LEU - GMALL T-LBL 1/2004 Reinduction |
| 392511000210106 |
LEU - GMALL T-LBL 1/2004 HDMTX/ASP [over 55 years] |
| 392501000210109 |
LEU - GMALL T-LBL 1/2004 Consolidation I [over 55 years] |
| 392491000210104 |
LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [over 55 years] |
| 392481000210101 |
LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [over 55 years] |
| 392471000210103 |
LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis High Risk |
| 392461000210109 |
LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis Unknown Risk [default] |
| 392451000210106 |
LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis High Risk |
| 392441000210108 |
LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis Unknown Risk [default] |
| 392431000210100 |
LEU ALL - HyperCVAD with pegaspargase Part A and B followed by POMP Maintenance [under 40 years] |
| 392421000210102 |
LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Consolidation/delayed intensification [Cycle 3] |
| 392411000210107 |
LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Intensification/CNS prophylaxis |
| 392401000210105 |
LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [not for transplant] |
| 392391000210107 |
LEU - UKALL14 with RITUximab [not for transplant] Maintenance |
| 392381000210105 |
LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Consolidation/delayed intensification [Cycle 3] |
| 392371000210108 |
LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Intensification/CNS prophylaxis |
| 392361000210102 |
LEU - UKALL14 with RITUximab [not for transplant] Phase 2 Induction |
| 392351000210100 |
LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [not for transplant] |
| 392341000210103 |
LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis High Risk |
| 392331000210106 |
LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis Unknown Risk [default] |
| 392321000210109 |
LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis High Risk |
| 392311000210104 |
LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis Unknown Risk [default] |
| 392301000210101 |
LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [60 years and under] |
| 392291000210100 |
LEU - HyperCVAD with RITUximab [over 60 years] Part B with Intrathecal CNS prophylaxis High Risk |
| 392281000210102 |
LEU - HyperCVAD Part B with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 391941000210106 |
LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis High Risk |
| 391931000210103 |
LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 391921000210100 |
LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [over 60 years] |
| 391911000210105 |
LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Consolidation/delayed intensification [Cycle 3] |
| 391901000210108 |
LEU - UKALL14 with RITUximab [40 years and under] Consolidation [Cycle 1 and 2] |
| 391891000210107 |
LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Intensification/CNS prophylaxis |
| 391881000210105 |
LEU - UKALL14 with RITUximab [40 years and under] Phase 1 Induction |
| 391871000210108 |
LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [for transplant] |
| 391861000210102 |
LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [40 years and under] |
| 391851000210100 |
LEU - UKALL14 Consolidation [Cycle 1] [40 years and under] |
| 391841000210103 |
LEU - UKALL14 Intensification/CNS prophylaxis [40 years and under] |
| 391831000210106 |
LEU - UKALL14 Phase 1 Induction [40 years and under] |
| 391821000210109 |
LEU ALL - UKALL14 [40 years and under] |
| 391811000210104 |
LEU - UKALL14 with RITUximab Consolidation [Cycle 4] |
| 391801000210101 |
LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Consolidation/delayed intensification [Cycle 3] |
| 391791000210100 |
LEU - UKALL14 with RITUximab [over 40 years] Consolidation [Cycle 1 and 2] |
| 391781000210102 |
LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Intensification/CNS prophylaxis |
| 391771000210104 |
LEU - UKALL14 with RITUximab [for transplant] Phase 2 Induction |
| 391761000210105 |
LEU - UKALL14 with RITUximab [over 40 years] Phase 1 Induction |
| 391751000210107 |
LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [for transplant] |
| 391741000210109 |
LEU - AIDA consolidation 3 [over 70 years] |
| 391731000210101 |
LEU - AIDA consolidation 2 [over 70 years] |
| 391721000210103 |
LEU - AIDA consolidation 1 [over 70 years] |
| 391711000210108 |
LEU - AIDA induction [over 70 years] |
| 391701000210106 |
LEU APL - AIDA induction and consolidations 1, 2 and 3 [over 70 years] |
| 391691000210106 |
LEU AML - DA+GO-1 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk] |
| 391681000210109 |
LEU - Pethema LPA2005 maintenance [70 years and under] [low risk] |
| 391671000210107 |
LEU - Pethema LPA2005 consolidation 3 [70 years and under] [low risk] |
| 391661000210101 |
LEU - Pethema LPA2005 consolidation 2 [70 years and under] [low risk] |
| 391621000210108 |
LEU - Pethema LPA2005 consolidation 1 [70 years and under] [low risk] |
| 391601000210100 |
LEU - Pethema LPA2005 induction [70 years and under] [low risk] |
| 391591000210105 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [low risk] |
| 391581000210108 |
LEU - Pethema LPA2005 maintenance [over 70 years] [low risk] |
| 391571000210106 |
LEU - Pethema LPA2005 consolidation 3 [over 70 years] [low risk] |
| 391561000210100 |
LEU - Pethema LPA2005 consolidation 2 [over 70 years] [low risk] |
| 391551000210103 |
LEU - Pethema LPA2005 consolidation 1 [over 70 years] [low risk] |
| 391541000210101 |
LEU - Pethema LPA2005 induction [over 70 years] [low risk] |
| 391531000210109 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [low risk] |
| 391521000210107 |
LEU - Pethema LPA2005 maintenance [over 70 years] [high risk] |
| 391511000210102 |
LEU - Pethema LPA2005 consolidation 3 [over 70 years] [high risk] |
| 391501000210104 |
LEU - Pethema LPA2005 consolidation 2 [over 70 years] [high risk] |
| 391491000210109 |
LEU - Pethema LPA2005 consolidation 1 [over 70 years] [high risk] |
| 391481000210107 |
LEU - Pethema LPA2005 induction [over 70 years] [high risk] |
| 391471000210105 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [high risk] |
| 391461000210104 |
GU GCT Seminoma Adjuvant - cARBOplatin [7 AUC] |
| 391451000210102 |
GU URO Advanced - cISplatin and gemcitabine |
| 391441000210100 |
GU URO Advanced - cISplatin [split dose] and gemcitabine |
| 391431000210108 |
GU Upper Tract Urothelial Adjuvant - cISplatin [split dose] and gemcitabine |
| 391421000210106 |
GU GCT Metastatic - TIP [PACLItaxel, IFOSFamide and cISplatin] |
| 391411000210101 |
LEU - Pethema LPA2005 maintenance [over 70 years] [intermediate risk] |
| 312741000210103 |
LEU - Pethema LPA2005 consolidation 3 [over 70 years] [intermediate risk] |
| 312731000210106 |
LEU - Pethema LPA2005 consolidation 2 [over 70 years] [intermediate risk] |
| 312721000210109 |
LEU - Pethema LPA2005 consolidation 1 [over 70 years] [intermediate risk] |
| 312711000210104 |
LEU - Pethema LPA2005 induction [over 70 years] [intermediate risk] |
| 312701000210101 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [intermediate risk] |
| 312691000210101 |
LEU - Pethema LPA2005 maintenance [under 60 years] [high risk] |
| 312681000210103 |
LEU - Pethema LPA2005 consolidation 3 [under 60 years] [high risk] |
| 312671000210100 |
LEU - Pethema LPA2005 consolidation 2 [under 60 years] [high risk] |
| 312661000210106 |
LEU - Pethema LPA2005 consolidation 1 [under 60 years] [high risk] |
| 312651000210108 |
LEU - Pethema LPA2005 induction [under 60 years] [high risk] |
| 312631000210102 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [under 60 years] [high risk] |
| 312621000210104 |
LEU - Pethema LPA2005 maintenance [60 to 70 years] [high risk] |
| 312611000210109 |
LEU - Pethema LPA2005 consolidation 3 [60 to 70 years] [high risk] |
| 312601000210107 |
LEU - Pethema LPA2005 consolidation 2 [60 to 70 years] [high risk] |
| 312591000210102 |
LEU - Pethema LPA2005 consolidation 1 [60 to 70 years] [high risk] |
| 312581000210104 |
LEU - Pethema LPA2005 induction [60 to 70 years] [high risk] |
| 312571000210101 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [60 to 70 years] [high risk] |
| 312561000210107 |
LEU - UKALL14 Maintenance |
| 312551000210109 |
LEU - UKALL14 Consolidation [Cycle 4] |
| 312541000210106 |
LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [over 40 years] |
| 312531000210103 |
LEU - UKALL14 Consolidation [Cycle 2] |
| 312521000210100 |
LEU - UKALL14 Consolidation [Cycle 1] [over 40 years] |
| 312511000210105 |
LEU - UKALL14 Intensification/CNS prophylaxis [over 40 years] |
| 312501000210108 |
LEU - UKALL14 - Phase 2 Induction |
| 312491000210103 |
LEU - UKALL14 [over 40 years] - Phase 1 Induction |
| 312481000210100 |
LEU ALL - UKALL14 [over 40 years] |
| 312471000210102 |
LYM NHL B-cell - O-CHOP21 [oBINUTUZumab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] |
| 312461000210108 |
LYM - DA-R-EPOCH LEVEL 6 |
| 312451000210105 |
LYM - DA-R-EPOCH LEVEL 5 |
| 312441000210107 |
LYM - DA-R-EPOCH LEVEL 4 |
| 312431000210104 |
LYM - DA-R-EPOCH LEVEL 3 |
| 312421000210101 |
LYM - DA-R-EPOCH LEVEL 2 |
| 312411000210106 |
LYM - DA-R-EPOCH LEVEL minus 3 |
| 312401000210109 |
LYM - DA-R-EPOCH LEVEL minus 2 |
| 312391000210106 |
LYM - DA-R-EPOCH LEVEL minus 1 |
| 312381000210109 |
LYM - DA-R-EPOCH LEVEL 1 |
| 312371000210107 |
LYM NHL B-cell - DA-R-EPOCH [Dose-adjusted RITUximab, etoposide, prEDNIsone, vinCRISTine, CYCLOPHOSPHamide and DOXOrubicin] [9 levels] |
| 312361000210101 |
LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis High Risk |
| 312351000210104 |
LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 312341000210102 |
LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis High Risk |
| 312331000210105 |
LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 312321000210108 |
LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [60 years and under] |
| 312311000210103 |
LEU - HyperCVAD POMP Maintenance |
| 312301000210100 |
LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis High Risk |
| 312291000210104 |
LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 312281000210101 |
LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis High Risk |
| 312271000210103 |
LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 312261000210109 |
LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [over 60 years] |
| 312251000210106 |
SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q2W] |
| 312241000210108 |
SAR Ewing sarcoma - VAC, VC and IE [Q2W] |
| 312231000210100 |
SAR - VAC + VV [vinCRISTine day 1, 8 and 15, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk] |
| 312221000210102 |
SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk] |
| 312211000210107 |
SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q3W] ARST0431 [high risk] |
| 312201000210105 |
SAR - IE [IFOSFamide and etoposide] [Q3W] ARST0431 [high risk] |
| 312191000210108 |
SAR - IE [IFOSFamide and etoposide] [Q2W] ARST0431 [high risk] |
| 312181000210106 |
SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q2W] ARST0431 [high risk] |
| 312171000210109 |
SAR - vinCRISTine days 1 and 8 and irinotecan ARST0431 [high risk] |
| 312161000210103 |
SAR - vinCRISTine days 1, 8 and 15 and irinotecan ARST0431 [high risk] |
| 312151000210101 |
SAR Rhabdomyosarcoma - vinCRISTine, irinotecan, IFOSFamide, etoposide, DOXOrubicin, CYCLOPHOSPHamide and daCTINomycin [ARST0431] [high risk] |
| 312141000210104 |
SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q3W] |
| 312131000210107 |
SAR Ewing sarcoma - VAC, VC and IE [Q3W] |
| 312121000210105 |
SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q3W] |
| 312111000210100 |
SAR - IE [IFOSfamide and etoposide][Q3W] |
| 312101000210102 |
SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] [Q3W] |
| 312091000210109 |
SAR Ewing sarcoma - VDC, VC and IE [Q3W] |
| 312081000210107 |
SAR - MA [metHOTREXATe and DOXOrubicin] |
| 312071000210105 |
SAR - MAP [metHOTREXATe, DOXOrubicin and cISplatin] |
| 312061000210104 |
SAR Osteosarcoma - MAP [metHOTREXATe, DOXOrubicin and cISplatin] |
| 312051000210102 |
PCN MM - pamidronate 90mg Q4W |
| 312041000210100 |
LEU ALL precursor B-cell - blinatumomab [CNS1 and CNS2] |
| 312031000210108 |
LEU ALL precursor B-cell - blinatumomab [CNS3] |
| 312021000210106 |
CRC REC Locally advanced - dostarlimab |
| 312011000210101 |
CRC - mFOLFOX6 [low dose foliNIc acid] 9 cycles |
| 312001000210103 |
CRC - mFOLFOX6 [high dose foliNIc acid] 9 cycles |
| 311991000210101 |
CRC - CAPOX 6 cycles |
| 311981000210103 |
CRC REC Neoadjuvant - RAPIDO Total Neoadjuvant Therapy |
| 311971000210100 |
CRC Metastatic - irinotecan [Q3W] dose reduced |
| 311961000210106 |
CRC Metastatic - CETUximab Q2W |
| 311951000210108 |
CRC Metastatic - trifluridine/tipiracil and beVACizumab |
| 311941000210105 |
CRC Metastatic - trifluridine/tipiracil |
| 311931000210102 |
CRC Metastatic - pembrolizumab Q6W [flat dosing] |
| 311921000210104 |
CRC Locally advanced - ipilimumab and nivolumab |
| 311911000210109 |
CRC Metastatic - pembrolizumab Q3W [flat dosing] |
| 311901000210107 |
CRC Metastatic - CETUximab [Q2W] and encorafenib |
| 311891000210106 |
CRC Metastatic - CETUximab [Q2W] and daBRAFEnib |
| 311881000210109 |
LEU - AIDA consolidation 3 [70 years and under] |
| 311871000210107 |
LEU - AIDA consolidation 2 [70 years and under] |
| 311861000210101 |
LEU - AIDA consolidation 1 [70 years and under] |
| 311851000210104 |
LEU - AIDA induction [70 years and under] |
| 311841000210102 |
LEU APL - AIDA induction and consolidations 1, 2 and 3 [70 years and under] |
| 311831000210105 |
LEU - arsenic trioxide and tretinoin consolidation [AML17] |
| 311821000210108 |
LEU - arsenic trioxide and tretinoin induction [AML17] |
| 311811000210103 |
LEU APL - arsenic trioxide and tretinoin induction followed by consolidation [AML17] |
| 311801000210100 |
LEU - APML4 maintenance [61 to 70 years] |
| 311791000210104 |
LEU - APML4 consolidation 2 [61 to 70 years] |
| 311781000210101 |
LEU - APML4 consolidation 1 [61 to 70 years] |
| 311771000210103 |
LEU - APML4 induction [61 to 70 years] |
| 311761000210109 |
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [61 to 70 years] |
| 311751000210106 |
LEU - APML4 maintenance [over 70 years] |
| 311741000210108 |
LEU - APML4 consolidation 2 [over 70 years] |
| 311721000210102 |
LEU - APML4 consolidation 1 [over 70 years] |
| 311711000210107 |
LEU - APML4 induction [over 70 years] |
| 311701000210105 |
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [over 70 years] |
| 311691000210105 |
LEU - Pethema LPA2005 maintenance [70 years and under] [intermediate risk] |
| 311681000210108 |
LEU - Pethema LPA2005 consolidation 3 [70 years and under] [intermediate risk] |
| 311671000210106 |
LEU - Pethema LPA2005 consolidation 2 [70 years and under] [intermediate risk] |
| 311661000210100 |
LEU - Pethema LPA2005 consolidation 1 [70 years and under] [intermediate risk] |
| 311651000210103 |
LEU - Pethema LPA2005 induction [70 years and under] [intermediate risk] |
| 311641000210101 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [intermediate risk] |
| 311631000210109 |
LEU HCL - cladribine and RITUximab |
| 311621000210107 |
LEU - arsenic trioxide and tretinoin consolidation [standard risk] |
| 311611000210102 |
LEU - arsenic trioxide, tretinoin and prEDNISone induction [standard risk] |
| 311601000210104 |
LEU APL - arsenic trioxide, tretinoin and prEDNISone induction followed by consolidation [standard risk] |
| 311591000210109 |
LEU - APML4 maintenance [60 years and under] |
| 311581000210107 |
LEU - APML4 consolidation 2 [60 years and under] |
| 311571000210105 |
LEU - APML4 consolidation 1 [60 years and under] |
| 311561000210104 |
LEU - APML4 induction [60 years and under] |
| 311551000210102 |
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [60 years and under] |
| 311541000210100 |
LEU - UKALL14 with daSATinib Maintenance |
| 311531000210108 |
LEU - UKALL14 with daSATinib Consolidation [Cycle 4] |
| 311521000210106 |
LEU - UKALL14 with daSATinib consolidation/delayed intensification [Cycle 3] |
| 311511000210101 |
LEU - UKALL14 with daSATinib Consolidation [Cycle 1 and 2] |
| 311501000210103 |
LEU - UKALL14 with daSATinib Intensification/CNS prophylaxis |
| 311491000210108 |
LEU - UKALL14 with daSATinib Phase 2 Induction |
| 311481000210106 |
LEU - UKALL14 with daSATinib Phase 1 Induction |
| 311471000210109 |
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with daSATinib |
| 311461000210103 |
LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Maintenance |
| 311451000210101 |
LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Consolidation/delayed intensification [Cycle 3] |
| 311441000210104 |
LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Intensification/CNS prophylaxis |
| 311431000210107 |
LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Phase 2 Induction |
| 311421000210105 |
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [not for transplant] |
| 311411000210100 |
LYM - High dose cytarabine [2000mg/m2 TWICE daily days 1 and 2] Consolidation |
| 311401000210102 |
LYM - R-MPV alternating with R-MV |
| 311391000210100 |
LYM NHL B-cell PCNSL - R-MPV [RITUximab, metHOTREXATe, procarbazine and vinCRISTine] followed by high dose cytarabine |
| 311381000210102 |
LYM - EA [etoposide and cytarabine] |
| 311371000210104 |
LYM - MT-R |
| 311361000210105 |
LYM NHL B-cell PCNSL - MT-R [metHOTREXate, temozolomide and RITUximab] followed by EA [etoposide and cytarabine] |
| 311351000210107 |
LYM NHL B-cell Primary Testicular - high dose metHOTREXATe [CNS prophylaxis] |
| 311341000210109 |
LYM NHL B-cell PCNSL - MATRix [metHOTREXATe, cytarabine, thiotepa and RITUximab] Induction |
| 311331000210101 |
LEU CLL Relapsed - aLEMTUzumab [subcut] |
| 311321000210103 |
LEU CLL - venetoclax and oBINUTUZumab |
| 311311000210108 |
LEU CLL - RITUximab and bendamustine |
| 311301000210106 |
LEU CLL Relapsed - aLEMTUzumab [IV] |
| 311291000210107 |
LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 4] |
| 311281000210105 |
LEU - UKALL14 with RITUximab and daSATinib consolidation/delayed intensification [Cycle 3] [for transplant] |
| 311271000210108 |
LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 1 and 2] |
| 311261000210102 |
LEU - UKALL14 with RITUximab and daSATinib [for transplant] Intensification/CNS prophylaxis |
| 311251000210100 |
LEU - UKALL14 with RITUximab and daSATinib Phase 2 Induction [for transplant] |
| 311241000210103 |
LEU - UKALL14 with RITUximab and daSATinib Phase 1 Induction |
| 311231000210106 |
LEU - dexamethasone 6 mg/m2 days 1 to 5 |
| 311221000210109 |
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [for transplant] |
| 311211000210104 |
LYM - oBINUTUZumab maintenance |
| 311201000210101 |
LYM - bendamustine and oBINUTUZumab |
| 311191000210103 |
LYM NHL B-cell - bendamustine and oBINUTUZumab |
| 311181000210100 |
LYM NHL NK/T-cell Extra Nodal - DDGP [dexamethasone, cISplatin, gemcitabine and pegaspargase] |
| 311171000210102 |
LEU CLL - venetoclax and RITUximab |
| 311161000210108 |
LEU - imatinib 600 |
| 311151000210105 |
LEU - imatinib 400 |
| 311141000210107 |
LEU CML - imatinib |
| 311131000210104 |
LYM NHL B-cell - Flyer R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] followed by RITUximab |
| 311121000210101 |
LEU - UKALL60+ Maintenance |
| 311111000210106 |
LEU - UKALL60+ Consolidation |
| 311101000210109 |
LEU - UKALL60+ Phase 2 Induction |
| 311091000210102 |
LEU - UKALL60+ Phase 1 Induction |
| 311081000210104 |
LEU ALL - UKALL60+ [non-intensive] |
| 311071000210101 |
LEU - UKALL60+ with daSATinib Maintenance |
| 311061000210107 |
LEU - UKALL60+ with daSATinib Consolidation |
| 311051000210109 |
LEU - UKALL60+ with daSATinib Phase 2 Induction |
| 311041000210106 |
LEU - UKALL60+ with daSATinib Phase 1 Induction |
| 311031000210103 |
LEU ALL BCR-ABL1+ - UKALL60+ with daSATinib |
| 311021000210100 |
LEU - UKALL60+ with imatinib Maintenance |
| 311011000210105 |
LEU - UKALL60+ with imatinib Consolidation |
| 311001000210108 |
LEU - UKALL60+ with imatinib Phase 2 Induction |
| 310991000210109 |
LEU - UKALL60+ with imatinib Phase 1 Induction |
| 310981000210107 |
LEU - dexamethasone 6 mg/m2 [max 10 mg] days 1 to 5 |
| 310971000210105 |
LEU ALL BCR-ABL1+ - UKALL60+ with imatinib |
| 310961000210104 |
LEU AML - DA+GO-2 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk] |
| 310951000210102 |
LEU AML - 7 + 3 IDA [IDArubicin and cytarabine] induction |
| 310941000210100 |
LEU - High dose cytarabine [1000mg/m2 TWICE daily days 1 to 6] consolidation |
| 310931000210108 |
LEU - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction [over 60 years] |
| 303631000210108 |
LEU AML - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction followed by high dose cytarabine consolidation [over 60 years] |
| 303621000210106 |
LEU - High dose cytarabine and midostaurin consolidation [under 60 years] |
| 303611000210101 |
LEU - DAUNOrubicin, cytarabine and midostaurin induction [under 60 years] |
| 303601000210103 |
LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [under 60 years] |
| 303591000210108 |
LEU - Midostaurin maintenance |
| 303581000210106 |
LEU - High dose cytarabine and midostaurin consolidation [60 years and over] |
| 303571000210109 |
LEU - DAUNOrubicin, cytarabine and midostaurin induction [60 years and over] |
| 303561000210103 |
LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [60 years and over] |
| 303551000210101 |
LEU - Manchester Protocol [mitoxantrone and cytarabine IV] consolidation |
| 303541000210104 |
LEU - Manchester Protocol [mitoxantrone and cytarabine IV] induction |
| 303531000210107 |
LEU AML - Manchester Protocol [mitoxantrone and cytarabine IV] induction followed by consolidation |
| 303521000210105 |
LYM NHL B-cell PCNSL Relapsed - R-IE [RITUximab, IFOSFamide and etoposide] |
| 303511000210100 |
LYM - procarbazine [100 mg daily for 5 days] |
| 303501000210102 |
LYM - R-MP [RITUximab, metHOTREXATe, procarbazine] [65 years and over] |
| 303491000210107 |
LYM NHL B-cell PCNSL - R-MP [RITUximab, metHOTREXATe and procarbazine] followed by procarbazine maintenance [65 years and over] |
| 303481000210105 |
LYM NHL B-cell - RITUximab and bendamustine |
| 303471000210108 |
LYM NHL B-cell - RITUximab Maintenance Q8W |
| 303461000210102 |
LYM NHL B-cell - RITUximab Q1W |
| 303451000210100 |
GYN CX Advanced - cISplatin, PACLItaxel, beVACizumab and pembrolizumab |
| 303441000210103 |
GYN CX Advanced - cISplatin, PACLItaxel and pembrolizumab |
| 274651000210101 |
GYN CX Advanced - cISplatin, PACLItaxel and beVACizumab |
| 265811000210107 |
LYM NHL - vinCRISTine and prEDNISone [pre-phase] |
| 265801000210105 |
LYM NHL B-cell PCNSL - high dose metHOTREXATe 8 g/m2 |
| 265791000210106 |
LYM NHL B-cell - CYCLOPHOSPHamide and prEDNIsone [pre-phase] |
| 265781000210109 |
LYM Relapsed - GIVE [filgrastim, IFOSFamide, etoposide and epirubicin] |
| 265771000210107 |
LYM Relapsed - DHAP [dexamethasone, high dose cytarabine and cISplatin] |
| 265761000210101 |
LYM NHL NK/T-cell Extra Nodal - Level 2 [100%] DeVIC [dexamethasone, etoposide, IFOSFamide, cARBOplatin] chemoradiation [nasal type] |
| 265751000210104 |
LYM NHL NK/T-cell Extra Nodal - Level 1 [67%] DeVIC [dexamethasone, etoposide, IFOSFamide, cARBOplatin] chemoradiation [nasal type] |
| 265741000210102 |
LYM NHL B-cell Relapsed - R-DHAP [RITUximab, dexamethasone, high dose cytarabine and cISplatin] |
| 265731000210105 |
Neuroendocrine neoplasm Advanced - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 265721000210108 |
Neuroendocrine carcinoma Advanced - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 265711000210103 |
Neuroendocrine carcinoma - cISplatin and etoposide 60/120 chemoradiation |
| 265701000210100 |
Neuroendocrine carcinoma - cISplatin and etoposide 80/100 chemoradiation |
| 265691000210100 |
Desmoid fibromatosis - metHOTREXATe and vinBLASTine |
| 265681000210102 |
SAR STS Metastatic - DOCEtaxel and gemcitabine 900 |
| 265671000210104 |
SAR STS Metastatic - DOCEtaxel and gemcitabine 675 [GeDDis] |
| 265661000210105 |
SAR STS Advanced - trabectedin |
| 265651000210107 |
SAR STS Advanced - pAZOPanib |
| 265641000210109 |
SAR STS Advanced - IFOSFamide [3-day] |
| 265631000210101 |
SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q2W] |
| 265621000210103 |
SAR - IE [IFOSfamide and etoposide][Q2W] |
| 265611000210108 |
SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] with dexrazoxane [Q2W] |
| 265601000210106 |
SAR Ewing sarcoma - VDC with dexrazoxane, VC and IE [Q2W] |
| 265591000210101 |
SAR STS Advanced - DOXOrubicin and IFOSFamide 25/3000 |
| 265581000210103 |
SAR STS Advanced - DOXOrubicin and IFOSFamide 20/2000 |
| 265571000210100 |
SAR Osteosarcoma Advanced - DOXOrubicin [1-day dosing] and cISplatin |
| 265561000210106 |
SAR Ewing sarcoma Relapsed - CYCLOPHOSPHamide and topotecan |
| 265551000210108 |
SAR Rhabdomyosarcoma Relapsed - VIT [vinCRISTine, irinotecan and temozolomide] |
| 265541000210105 |
SAR Osteosarcoma Advanced - DOXOrubicin [3-day split dosing] and cISplatin |
| 265531000210102 |
LYM NHL B-cell - R-MiniCHOP [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] |
| 265521000210104 |
Neuroendocrine carcinoma Advanced - cARBOplatin and oral etoposide |
| 265511000210109 |
Neuroendocrine tumour Advanced - everolimus |
| 265501000210107 |
Neuroendocrine tumour PANC Advanced - sUNITinib |
| 265491000210102 |
Neuroendocrine carcinoma Advanced - cARBOplatin and etoposide |
| 265481000210104 |
GU Renal cell Metastatic - beVACizumab and erlotinib |
| 265471000210101 |
GU GCT Advanced - EP [etoposide and cISplatin] [3-day] |
| 265461000210107 |
GU GCT Metastatic - BEP [bleomycin, etoposide and cISplatin] [3-day] |
| 265451000210109 |
GU Bladder Urothelial - cISplatin [Q1W] chemoradiation |
| 265441000210106 |
GU URO Advanced - avelumab Q2W [flat dosing] |
| 265431000210103 |
GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing] and ipilimumab |
| 265421000210100 |
GU Renal cell Metastatic - cABOZANtinib and nivolumab |
| 265411000210105 |
GU Renal cell Metastatic - aXITinib and avelumab [flat dose] |
| 265401000210108 |
GU - nivolumab maintenance Q2W [flat dosing] |
| 265391000210105 |
GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q2W [flat dosing] |
| 265381000210108 |
GU - nivolumab maintenance Q4W [flat dosing] |
| 265371000210106 |
GU - nivolumab and ipilimumab induction |
| 265361000210100 |
GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q4W [flat dosing] |
| 265351000210103 |
GU URO Metastatic - PACLItaxel Q1W and pembrolizumab Q3W [flat dosing] |
| 265341000210101 |
GU Renal cell Metastatic - leNVAtinib and everolimus |
| 265331000210109 |
GU Bladder Urothelial - gemcitabine [low dose] chemoradiation |
| 265321000210107 |
GU Bladder Urothelial Neoadjuvant - ddMVAC [metHOTREXATe, DOXOrubicin, vinBLASTine and cISplatin] dose dense |
| 265311000210102 |
GU Bladder Urothelial Adjuvant - ddMVAC [metHOTREXATe, DOXOrubicin, vinBLASTine and cISplatin] dose dense |
| 265301000210104 |
GU Penile Advanced - TIP [PACLItaxel, IFOSFamide and cISplatin] [3-day] |
| 265291000210103 |
GU Penile Advanced - TIP [PACLItaxel, IFOSFamide and cISplatin] [5-day] |
| 265281000210100 |
GU Penile Advanced - TPF [DOCEtaxel, cISplatin, fluorouracil] |
| 265271000210102 |
CRC ACA - cISplatin and fluorouracil chemoradiation |
| 265261000210108 |
CRC ACA - mitomycin and capecitabine chemoradiation |
| 265251000210105 |
CRC ACA - mitomycin and fluorouracil chemoradiation |
| 265241000210107 |
UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin] and nivolumab |
| 265231000210104 |
UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin], pembrolizumab and trastuzumab |
| 265221000210101 |
UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] and nivolumab |
| 265211000210106 |
UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] and nivolumab |
| 265201000210109 |
CRC Metastatic - CETUximab [Q1W], daBRAFEnib and tRAMEtinib |
| 265191000210107 |
GU URO Metastatic - PACLItaxel [Q1W] |
| 265181000210105 |
GU Renal cell Metastatic - leNVAtinib and pembrolizumab Q3W [flat dosing] |
| 265171000210108 |
GU Renal cell Advanced - nivolumab Q2W [flat dosing] |
| 265161000210102 |
GU Renal cell Advanced - nivolumab Q4W [flat dosing] |
| 265151000210100 |
GU Renal cell Metastatic - pAZOPanib |
| 265141000210103 |
GU Renal cell Metastatic - sUNITinib |
| 265131000210106 |
GU URO Advanced - pembrolizumab Q3W [flat dosing] |
| 265121000210109 |
GU URO Advanced - pembrolizumab Q6W [flat dosing] |
| 265111000210104 |
GU Renal cell Metastatic - aXITinib and pembrolizumab Q3W [flat dosing] |
| 265101000210101 |
GU Renal cell Metastatic - aXITinib and pembrolizumab Q6W [flat dosing] |
| 265091000210108 |
GU Renal cell Metastatic - everolimus |
| 265081000210106 |
GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing] |
| 265071000210109 |
GU Renal cell Metastatic - pembrolizumab Q6W [flat dosing] |
| 265061000210103 |
GU Bladder Urothelial Neoadjuvant - cISplatin and gemcitabine |
| 265051000210101 |
GU BLA - mitomycin and fluorouracil chemoradiation |
| 265041000210104 |
GU GCT Metastatic - BEP [bleomycin, etoposide and cISplatin] [5-day] |
| 265031000210107 |
GU GCT Non-seminoma Adjuvant - BEP [bleomycin, etoposide and cISplatin] |
| 265021000210105 |
GU GCT Advanced - EP [etoposide and cISplatin] [5-day] |
| 265011000210100 |
GU GCT Metastatic - VIP [etoposide, IFOSFamide and cISplatin] |
| 265001000210102 |
GU URO Advanced - cARBOplatin and gemcitabine |
| 264991000210108 |
GU Upper Tract Urothelial Adjuvant - cARBOplatin and gemcitabine |
| 264981000210106 |
GU Upper Tract Urothelial Adjuvant - cISplatin and gemcitabine |
| 264971000210109 |
GU Renal cell Metastatic - cABOZANtinib |
| 264961000210103 |
GU Renal cell Metastatic - aXITinib |
| 264951000210101 |
LYM Relapsed/Refractory - pembrolizumab Q3W [flat dosing] |
| 264941000210104 |
LEU CML - pONATinib |
| 264931000210107 |
LYM - GemOx [gemcitabine and oxaliplatin] |
| 264921000210105 |
LYM Relapsed - DHAC [dexamethasone, high dose cytarabine and cARBOplatin] |
| 264911000210100 |
LYM NHL B-cell Relapsed - R-DHAC [RITUximab, dexamethasone, high dose cytarabine and cARBOplatin] |
| 264901000210102 |
LYM NHL B-cell PCNSL Relapsed - modified CYVE [cytarabine and etoposide] |
| 264891000210103 |
MPN Myelofibrosis - ruxolitinib |
| 264881000210100 |
LEU HCL - RITUximab |
| 264871000210102 |
LEU T-PLL Relapsed - pentostatin |
| 264861000210108 |
LEU T-PLL - aLEMTUzumab [IV] |
| 264851000210105 |
LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [3 day] |
| 264841000210107 |
LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [5 day] |
| 264831000210104 |
LEU CLL - FCR [IV] fludarabine, CYCLOPHOSPHamide and RITUximab |
| 264821000210101 |
LEU CLL - venetoclax |
| 264811000210106 |
LEU - daSATinib 140 |
| 264801000210109 |
LEU - daSATinib 100 |
| 264791000210105 |
LEU CML - daSATinib |
| 264781000210108 |
LEU HCL - cladribine |
| 264771000210106 |
PCN MM - lenalidomide and dexamethasone |
| 264761000210100 |
GYN VUL Advanced - ciSplatin [Q1W] chemoradiation |
| 264751000210103 |
LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and gemcitabine |
| 264741000210101 |
LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and vinORELBine |
| 264731000210109 |
SAR Ewing sarcoma Relapsed - irinotecan and temozolomide |
| 264721000210107 |
Desmoid fibromatosis - metHOTREXATe and vinORELBine |
| 264711000210102 |
SAR Advanced - pembrolizumab Q3W [flat dosing] |
| 264701000210104 |
SAR Advanced/Metastatic - pembrolizumab Q6W [flat dosing] |
| 264691000210104 |
SAR Angiosarcoma Advanced - PACLItaxel |
| 264681000210101 |
SAR Advanced - pembrolizumab Q3W [weight-based dosing] |
| 264671000210103 |
Giant Cell tumour of bone - denosumab |
| 264661000210109 |
SAR STS Advanced - DOXOrubicin |
| 264651000210106 |
SAR Kaposi Sarcoma - pegylated liposomal DOXOrubicin hydrochloride |
| 264641000210108 |
LYM NHL T-cell - CHOEP21 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV etoposide] |
| 264631000210100 |
LYM NHL T-cell - CHOEP21 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV/oral etoposide] |
| 264621000210102 |
LYM NHL B-cell - R-CVP [RITUximab, CYCLOPHOSPHamide, vinCRISTine and prEDNISone] |
| 264611000210107 |
LYM NHL B-cell - R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] |
| 264601000210105 |
LYM NHL B-cell Diffuse large - R-CEOP [RITUximab, CYCLOPHOSPHamide, etoposide, vinCRISTine and prEDNISone] [IV etoposide] |
| 264591000210100 |
LYM NHL B-cell Diffuse large - R-CEOP [RITUximab, CYCLOPHOSPHamide, etoposide, vinCRISTine and prEDNIsone] [IV/oral etoposide] |
| 264581000210102 |
LYM - vinORELBine and gemcitabine |
| 264571000210104 |
LYM NHL - CHOP21 [CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] |
| 264561000210105 |
LYM NHL B-cell - R-CHOP14 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] |
| 264551000210107 |
LYM NHL B-cell - R-CEPP [RITUximab, CYCLOPHOSPHamide, etoposide, procarbazine and prEDNISone] [IV/oral etoposide] |
| 264541000210109 |
LYM NHL B-cell - R-CEPP [RITUximab, CYCLOPHOSPHamide, etoposide, procarbazine and prEDNISone] [IV etoposide] |
| 264531000210101 |
LYM NHL B-cell - R-GDP [RITUximab, gemcitabine, dexamethasone and cISplatin] |
| 264521000210103 |
LYM NHL B-cell - R-GCVP [RITUximab, gemcitabine, CYCLOPHOSPHamide, vinCRISTine and prEDNISone] |
| 264511000210108 |
LYM - GDP [gemcitabine, dexamethasone and cISplatin] |
| 264501000210106 |
LYM - GCD [gemcitabine, cARBOplatin and dexamethasone] |
| 264491000210101 |
LYM NHL B-cell - R-GemOX [RITUximab, gemcitabine and oxaliplatin] |
| 264481000210103 |
LYM - PEP-C [prEDNISone, CYCLOPHOSPHamide, etoposide and procarbazine] |
| 264471000210100 |
CRC ACA Advanced - cARBOplatin and PACLItaxel |
| 264461000210106 |
CRC Metastatic - CETUximab [Q1W], biNIMEtinib and encorafenib |
| 264451000210108 |
CRC Metastatic - CETUximab [Q1W] and encorafenib |
| 264441000210105 |
LEU AML - MidAC [mitoxantrone and cytarabine] |
| 264431000210102 |
LEU CLL - acalabrutinib |
| 264411000210109 |
LEU CLL - chlorambucil and oBINUTUZumab |
| 264401000210107 |
LEU - nilotinib 300 |
| 264391000210109 |
LEU - nilotinib 400 |
| 264381000210107 |
LEU CML - nilotinib |
| 264371000210105 |
CNS GBM Recurrent - beVACizumab and irinotecan 340 mg/m2 |
| 264361000210104 |
LYM Relapsed - ICE [fractionated IFOSFamide, cARBOplatin and etoposide] |
| 264351000210102 |
LYM NHL B-cell Relapsed - R-ICE [RITUximab, fractionated IFOSFamide, cARBOplatin and etoposide] |
| 264341000210100 |
LYM NHL B-cell MCL - R-BAC [RITUximab, bendamustine and cytarabine] |
| 264331000210108 |
LYM NHL B-cell Lymphoplasmacytic - ibrutinib [Waldenström macroglobulinema] |
| 264321000210106 |
LYM HL Advanced - ChlVPP [chlorambucil, vinBLASTine, procarbazine and prEDNISone] |
| 264311000210101 |
LYM NHL B-cell MCL - ibrutinib |
| 264301000210103 |
LYM NHL T-cell - CHOEP14 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV/oral etoposide] |
| 264291000210102 |
LYM NHL T-cell - CHOEP14 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV etoposide] |
| 264281000210104 |
CNS GBM Recurrent - lomustine |
| 264271000210101 |
CNS GLI Recurrent - temozolomide [continuous dose-intense] [high grade] |
| 264261000210107 |
CNS GBM Recurrent - beVACizumab and irinotecan 125 mg/m2 |
| 264251000210109 |
CNS GLI Adjuvant - PCV [procarbazine, lomustine and vinCRISTine] [high grade] |
| 264241000210106 |
CNS GLI Adjuvant - PCV [procarbazine, lomustine and vinCRISTine] [low grade] |
| 264231000210103 |
LUNG NSCLC Metastatic - vinORELBine 30 [day 1 and 8] Q3W |
| 264221000210100 |
LUNG NSCLC Metastatic - vinORELBine 25 Q1W |
| 264211000210105 |
BR Adjuvant - EC-D [epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel] |
| 264201000210108 |
BR Metastatic - olaparib |
| 264191000210106 |
BR NON-Metastatic - D100-FEC [DOCEtaxel followed by fluorouracil, epirubicin and CYCLOPHOSPHamide] |
| 264181000210109 |
BR Neoadjuvant - cARBOplatin Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W |
| 264171000210107 |
BR NON-Metastatic - D75-FEC [DOCEtaxel followed by fluorouracil, epirubicin and CYCLOPHOSPHamide] |
| 264161000210101 |
BR NON-Metastatic - EC [epirubicin and CYCLOPHOSPHamide] |
| 264151000210104 |
LEU AML Relapsed - gilteritinib [FLT3 mutated] |
| 264141000210102 |
LEU AML Refractory - FLAG-Ida10 [fludarabine, cytarabine, filgrastim and IDArubicin] [under 60 years] |
| 264131000210105 |
LEU AML FLT3-ITD mutated Relapsed - azacitidine and soRAFENib |
| 264121000210108 |
LEU AML FLT3-ITD mutated - soRAFENib maintenance after allogeneic stem cell transplant |
| 264111000210103 |
LEU AML - azacitidine [7 day] |
| 264101000210100 |
LEU AML - azacitidine and venetoclax |
| 264091000210107 |
LEU AML - ALFA 9801 [IDArubicin and cytarabine] induction |
| 264081000210105 |
LEU AML - MACE [amsacrine, cytarabine and etoposide] |
| 264071000210108 |
LUNG NSCLC Locally advanced - durvalumab Q4W [flat dosing] |
| 264061000210102 |
PCN MM Relapsed - carfilzomib and dexamethasone [Q1W] |
| 264051000210100 |
PCN MM Relapsed - pomalidomide and dexamethasone |
| 264041000210103 |
PCN MM Relapsed - daratumumab [subcut] |
| 264031000210106 |
PCN MM Relapsed - daratumumab [subcut], bortezomib and dexamethasone [Q3W] followed by daratumumab [subcut] [Q4W] |
| 264021000210109 |
PCN MM Relapsed - LenBorDex [lenalidomide, bortezomib, and dexamethasone] Q4W |
| 264011000210104 |
PCN MM Relapsed - pomalidomide, bortezomib and dexamethasone |
| 264001000210101 |
Myelodysplastic syndrome - azacitidine [7 day] |
| 263991000210105 |
Myelodysplastic syndrome - azacitidine [5 day] |
| 263981000210108 |
LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [60 years and over] |
| 263971000210106 |
CNS GBM Recurrent - beVACizumab and lomustine |
| 263961000210100 |
CNS GBM Recurrent - beVACizumab Q2W |
| 263951000210103 |
CNS GBM Recurrent - beVACizumab Q3W |
| 263941000210101 |
CNS GLI Recurrent - temozolomide [high grade] |
| 263931000210109 |
CNS - temozolomide following chemoradiation |
| 263921000210107 |
CNS - temozolomide chemoradiation |
| 263911000210102 |
CNS GBM - temozolomide chemoradiation followed by temozolomide |
| 263901000210104 |
LUNG NSCLC Metastatic - pembrolizumab Q3W [flat dosing] |
| 263891000210100 |
LUNG SCLC Extensive - PACLItaxel Q1W |
| 263881000210102 |
LEU AML Relapsed - FLAG-amsacrine [fludarabine, cytarabine, filgrastim and amsacrine] [under 60 years] |
| 263871000210104 |
LEU AML Relapsed - FLAG-amsacrine [fludarabine, cytarabine, filgrastim and amsacrine] [60 years and over] |
| 263861000210105 |
LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [under 60 years] |
| 263851000210107 |
LEU CMML - azacitidine [7 day] |
| 263841000210109 |
LEU AML - cytarabine 3 g/m2 [ONCE daily days 1 to 6] consolidation [courses 3 and 4] |
| 263831000210101 |
LUNG NSCLC Metastatic - gemcitabine |
| 263821000210103 |
LUNG NSCLC Adjuvant - osimertinib |
| 60491000210104 |
LEU AML - low dose cytarabine |
| 60481000210101 |
LEU AML - low dose cytarabine and venetoclax |
| 60471000210103 |
LEU AML - DA 3+8 [DAUNOrubicin and cytarabine] induction [course 2] |
| 60461000210109 |
LEU AML - DA 3+10 [DAUNOrubicin and cytarabine] induction [course 1] |
| 60451000210106 |
LEU AML - cytarabine 3 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [under 60 years] |
| 60441000210108 |
LEU AML - cytarabine 1.5 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [60 years and over] |
| 60431000210100 |
LEU AML - cytarabine 3 g/m2 [days 1,2,3] consolidation [courses 3 and 4] [under 60 years] |
| 60421000210102 |
LEU AML - FLAG-Ida [fludarabine, cytarabine, filgrastim and IDArubicin] [under 60 years] |
| 60411000210107 |
LEU AML - FLAG-Ida [fludarabine, cytarabine, filgrastim and IDArubicin] [60 years and over] |
| 60401000210105 |
PCN MM - daratumumab [subcut], lenalidomide and dexamethasone |
| 60391000210107 |
PCN MM - lenalidomide [continuous dosing] post autologous stem cell transplant |
| 60381000210105 |
PCN MM - pamidronate 30mg Q4W |
| 60371000210108 |
PCN MM - zoledronic acid [Q12W] |
| 60361000210102 |
PCN MM - MP [melphalan and preDNISone] |
| 60351000210100 |
PCN MM - MPT [melphalan, prEDNISone and thalidomide] |
| 60341000210103 |
PCN MM - lenalidomide [3/1 dosing] post autologous stem cell transplant |
| 60331000210106 |
PCN MM - LenBorDex [lenalidomide, bortezomib, and dexamethasone] consolidation |
| 60321000210109 |
PCN MM - LenBorDex [lenalidomide, bortezomib, and dexamethasone] induction followed by autologous stem cell transplant |
| 60311000210104 |
PCN MM - ixazomib, lenalidomide and dexamethasone |
| 60301000210101 |
PCN MM - CyBorDex Low [CYCLOPHOSPHamide, bortezomib and dexamethasone] |
| 60291000210100 |
PCN - CTDa [CYCLOPHOSPHamide, thalidomide and dexamethasone] [attenuated dose] |
| 60281000210102 |
PCN MM - CyBorDex High [CYCLOPHOSPHamide, bortezomib and dexamethasone] |
| 60271000210104 |
PCN - CTD [CYCLOPHOSPHamide, thalidomide and dexamethasone] |
| 60261000210105 |
PCN MM - BTD [bortezomib, thalidomide and dexamethasone] induction |
| 60251000210107 |
PCN MM - BMP [bortezomib, melphalan and prEDNISone] |
| 60241000210109 |
MPN - busulfan |
| 60231000210101 |
HN NPC Metastatic - gemcitabine [Q4W] |
| 60221000210103 |
GYN Ovarian germ cell tumour - BEP [bleomycin, etoposide and cISplatin] |
| 60211000210108 |
GYN OV Recurrent - PACLitaxel [Q1W] and beVACizumab |
| 60201000210106 |
GYN OV Recurrent - PACLitaxel [Q1W] |
| 60191000210109 |
CRC Adjuvant - mDe Gramont [high dose foliNIc acid] |
| 60181000210107 |
CRC Adjuvant - mDe Gramont [low dose foliNIc acid] |
| 60171000210105 |
UGI BIL AND GBC Metastatic - cISplatin and gemcitabine |
| 60161000210104 |
UGI PANC Metastatic - gemcitabine and Abraxane [PACLItaxel nanoparticle albumin bound] |
| 60151000210102 |
LEU CLL - ibrutinib |
| 60141000210100 |
LEU CLL - chlorambucil |
| 60131000210108 |
LEU CLL - chlorambucil [flat dosing] |
| 60121000210106 |
HN SQCC Metastatic - metHOTREXATe |
| 60111000210101 |
HN SQCC NON-Metastatic - TPF [DOCEtaxel, ciSplatin and fluorouracil] followed by cARBOplatin chemoradiation |
| 60101000210103 |
HN SQCC NON-Metastatic - CETUximab chemoradiation |
| 60091000210105 |
GYN - cARBOplatin and PACLItaxel [following chemoradiation] |
| 60081000210108 |
GYN - cISplatin chemoradiation |
| 60071000210106 |
GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel |
| 60061000210100 |
GYN OV Recurrent - topotecan |
| 60051000210103 |
GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only] |
| 60041000210101 |
GYN VUL Advanced - CARBOplatin [Q1W] chemoradiation |
| 60031000210109 |
GYN OV Recurrent - topotecan and beVACizumab Q4W |
| 60021000210107 |
GYN GTD - TP-TE [PACLItaxel, cISplatin - PACLItaxel and etoposide] [relapsed or high risk] |
| 60011000210102 |
GYN GTD - EP-EMA [etoposide, ciSplatin, etoposide, metHOTREXATe and daCTINomycin] [high risk] |
| 60001000210104 |
GYN OV Low grade serous carcinoma - letrozole maintenance |
| 59991000210107 |
GYN OV Recurrent - CYCLOPHOSPHamide oral [2/4 dosing] |
| 59981000210105 |
GYN OV Recurrent - CYCLOPHOSPHamide oral [continuous] |
| 59971000210108 |
GYN OV Recurrent - etoposide oral |
| 59961000210102 |
GYN OV Recurrent - gemcitabine |
| 59951000210100 |
GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride |
| 59941000210103 |
GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride and beVACizumab |
| 59931000210106 |
GYN CX Locally advanced - cARBOplatin [Q1W] chemoradiation |
| 59921000210109 |
GYN CX Locally advanced - cISplatin [Q1W] chemoradiation |
| 59911000210104 |
GYN GTD - EMA-CO [etoposide, metHOTREXATe, daCTINomycin, CYCLOPHOSPHamide and vinCRISTine] [high risk] |
| 59901000210101 |
LUNG NSCLC Locally advanced - durvalumab Q2W [weight based dosing] |
| 59891000210102 |
GYN OV Recurrent - cARBOplatin and gemcitabine [day 1 cARBOplatin] |
| 59881000210104 |
GYN OV Recurrent - cARBOplatin and pegylated liposomal DOXOrubicin hydrochloride |
| 59871000210101 |
GYN OV Recurrent - cARBOplatin, gemcitabine and beVACizumab |
| 59861000210107 |
GYN OV Recurrent - cARBOplatin, pegylated liposomal DOXOrubicin hydrochloride and beVACizumab |
| 59851000210109 |
GYN GTD - EP [etoposide and cISplatin] [very high risk] |
| 59841000210106 |
BR NON-Metastatic - DOCEtaxel, pERTUZumab and trastuzumab |
| 59831000210103 |
BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 3/4] |
| 59821000210100 |
BR NON-Metastatic - cARBOplatin Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] dose dense |
| 59811000210105 |
BR Metastatic - CMF classical [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil] |
| 59801000210108 |
BR Metastatic - vinORELBine [IV], pERTUZumab and trastuzumab Q3W |
| 59791000210109 |
BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 2/3] |
| 59781000210107 |
BR Metastatic - vinORELBine [oral] |
| 59771000210105 |
GYN END Advanced - meDROXYPROGESTERone acetate |
| 59761000210104 |
GYN OV Advanced - beVACizumab 7.5 mg/kg Q3W [shared care] |
| 59751000210102 |
GYN OV Advanced - cARBOplatin [primary treatment] |
| 59731000210108 |
GYN CX Advanced - cISplatin and PACLItaxel |
| 59721000210106 |
GYN OV Advanced - cARBOplatin and DOCEtaxel |
| 59711000210101 |
GYN OV Advanced - cARBOplatin and PACLItaxel [Q1W] |
| 59701000210103 |
GYN OV Advanced - cARBOplatin and PACLitaxel [Q3W] |
| 59691000210103 |
GYN OV Advanced - cARBOplatin, PACLItaxel and beVACizumab |
| 59681000210100 |
GYN OV Recurrent - cARBOplatin |
| 59671000210102 |
GYN OV Advanced - olaparib |
| 59661000210108 |
GYN END Advanced - leNVAtinib and pembrolizumab Q3W [flat dosing] |
| 59651000210105 |
GYN OV Advanced - beVACizumab 15 mg/kg Q3W [shared care] |
| 59641000210107 |
GYN OV Adjuvant - cARBOplatin and PACLitaxel [early stage] |
| 59631000210104 |
GYN OV Adjuvant - cARBOplatin [early stage] |
| 59621000210101 |
GYN GTD - metHOTREXATe [low risk] |
| 59591000210104 |
GYN GTD - daCTINomycin [low risk] |
| 59581000210101 |
GYN - pembrolizumab Q3W [weight based dosing] |
| 59571000210103 |
GYN - pembrolizumab Q6W [flat dosing] |
| 59561000210109 |
GYN - pembrolizumab Q3W [flat dosing] |
| 59551000210106 |
GYN END Advanced - cARBOplatin and PACLItaxel |
| 59541000210108 |
GYN CX Advanced - cARBOplatin, PACLItaxel and beVACizumab |
| 59531000210100 |
GYN CX Advanced - cARBOplatin and PACLItaxel |
| 59521000210102 |
LUNG SCLC NON-Metastatic - [Limited] cISplatin and etoposide 80/100 chemoradiation |
| 59511000210107 |
HN THY Metastatic - leNVAtinib |
| 59501000210105 |
HN SQCC NON-Metastatic - cISplatin [Q3W] post-operative chemoradiation |
| 59491000210100 |
HN SQCC Metastatic - cARBOplatin and fluorouracil [Q3W] |
| 59481000210102 |
HN NPC NON-Metastatic - cARBOplatin chemoradiation followed by cARBOplatin and fluorouracil |
| 59471000210104 |
HN NPC NON-Metastatic - gemcitabine and cISplatin followed by cISplatin chemoradiation |
| 59461000210105 |
HN SAL Metastatic - cISplatin and vinORELBine [IV] |
| 59451000210107 |
HN SQCC NON-Metastatic - cISplatin [Q3W] chemoradiation |
| 59441000210109 |
HN NPC NON-Metastatic - cISplatin [Q3W] chemoradiation followed by cISplatin and fluorouracil |
| 59431000210101 |
HN SAL Metastatic - CAP [CYCLOPHOSPHamide, DOXOrubicin and cISplatin] |
| 59421000210103 |
HN SQCC Metastatic - cISplatin, fluorouracil and pembrolizumab |
| 59411000210108 |
HN SQCC Metastatic - nivolumab Q2W [flat dosing] |
| 59401000210106 |
HN SQCC Metastatic - PACLItaxel Q1W |
| 59391000210108 |
HN SQCC Metastatic - pembrolizumab Q3W [weight-based dosing] |
| 59381000210106 |
HN NPC Metastatic - gemcitabine and cARBOplatin |
| 59371000210109 |
HN SQCC Metastatic - cARBOplatin, fluorouracil and pembrolizumab |
| 59361000210103 |
HN NPC Metastatic - gemcitabine and cISplatin |
| 59351000210101 |
HN SQCC Metastatic - cARBOplatin and PACLItaxel |
| 59341000210104 |
HN SQCC Metastatic - cISplatin and fluorouracil |
| 59331000210107 |
HN NPC NON-Metastatic - cISplatin [Q1W] chemoradiation |
| 59321000210105 |
HN SQCC NON-Metastatic - cISplatin [Q1W] chemoradiation |
| 59311000210100 |
BR NON-Metastatic - CMF classical IV [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil] |
| 59301000210102 |
BR Metastatic - CMF classical IV [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil] |
| 59291000210101 |
LUNG NSCLC NON-Metastatic - cISplatin and gemcitabine chemoradiation |
| 59281000210103 |
LUNG NSCLC Metastatic - cISplatin and gemcitabine |
| 59271000210100 |
LUNG NSCLC NON-Metastatic - cISplatin and vinBLASTine chemoradiation |
| 59261000210106 |
GU PROS Metastatic - zoledronic acid Q6W |
| 59251000210108 |
HN SQCC Metastatic - nivolumab Q4W [flat dosing] |
| 59241000210105 |
HN SQCC NON-Metastatic - cISplatin [Q1W] post-operative chemoradiation |
| 59231000210102 |
HN SQCC NON-Metastatic - cARBOplatin and fluorouracil chemoradiation |
| 59221000210104 |
HN SQCC Metastatic - nivolumab [weight-based dosing] |
| 59211000210109 |
HN SQCC Metastatic - pembrolizumab Q6W [flat dosing] |
| 59201000210107 |
HN SQCC Metastatic - pembrolizumab Q3W [flat dosing] |
| 59191000210105 |
BR Metastatic - capecitabine 1000 and trastuzumab Q3W |
| 59181000210108 |
BR Metastatic - DOCEtaxel Q3W |
| 59171000210106 |
BR Metastatic - DOCEtaxel, pERTUZumab and trastuzumab |
| 59161000210100 |
BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by PACLItaxel Q1W |
| 59151000210103 |
BR Metastatic - DOCEtaxel and trastuzumab Q3W |
| 59141000210101 |
BR NON-Metastatic - FEC-D75 [fluorouracil, epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel] |
| 59131000210109 |
BR Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] |
| 59121000210107 |
BR NON-Metastatic - AC-TH [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by [DOCEtaxel and trastuzumab] Q3W |
| 59111000210102 |
UGI GAST AND OES Metastatic - DOCEtaxel |
| 59101000210104 |
UGI PANC NON-Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid] |
| 59091000210106 |
UGI PANC NON-Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 59081000210109 |
UGI PANC NON-Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 59071000210107 |
UGI PANC Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid] |
| 59051000210104 |
UGI PANC Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 59041000210102 |
UGI PANC Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 59031000210105 |
UGI PANC Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid] |
| 59021000210108 |
SKIN Melanoma NON-Metastatic - daBRAFEnib and tRAMEtinib |
| 59011000210103 |
LUNG NSCLC Metastatic - gefitinib |
| 59001000210100 |
LUNG SCLC NON-Metastatic - [Limited] cISplatin and etoposide 60/120 chemoradiation |
| 58991000210100 |
LUNG SCLC Extensive - cARBOplatin and oral etoposide |
| 58981000210102 |
LUNG NSCLC NON-Metastatic - cISplatin and vinORELBine Q4W |
| 58971000210104 |
LUNG SCLC Metastatic - [Extensive] cISplatin and irinotecan |
| 58961000210105 |
LUNG SCLC Extensive - cARBOplatin and etoposide |
| 58951000210107 |
LUNG NSCLC Metastatic - erlotinib |
| 58941000210109 |
LUNG NSCLC Metastatic - cISplatin and pemetrexed |
| 58931000210101 |
SKIN Melanoma Metastatic - daBRAFEnib and tRAMEtinib |
| 58921000210103 |
LUNG NSCLC NON-Metastatic - cISplatin and vinORELBine Q3W |
| 58911000210108 |
LUNG NSCLC Metastatic - cISplatin and vinORELBine |
| 58901000210106 |
LUNG NSCLC NON-Metastatic - cARBOplatin and PACLItaxel chemoradiation |
| 58891000210105 |
LUNG NSCLC Metastatic - cARBOplatin and PACLItaxel |
| 58881000210108 |
BR Metastatic - CYCLOPHOSPHamide and metHOTREXATe [low dose oral] |
| 58871000210106 |
BR NON-Metastatic - CMF classical [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil] |
| 58861000210100 |
BR NON-Metastatic - AC [DOXOrubicin and and CYCLOPHOSPHamide] dose dense followed by PACLItaxel dose dense |
| 58851000210103 |
BR NON-Metastatic - capecitabine |
| 58841000210101 |
BR Metastatic - zoledronic acid Q12W |
| 58831000210109 |
BR NON-Metastatic - TCy and trastuzumab [DOCEtaxel, CYCLOPHOSPHamide and trastuzumab] |
| 58821000210107 |
BR NON-Metastatic - trastuzumab Q3W |
| 58811000210102 |
BR NON-Metastatic - trastuzumab subcutaneous |
| 58801000210104 |
BR NON-Metastatic - exemestane and goserelin |
| 58791000210103 |
BR NON-Metastatic - PACLItaxel Q1W and trastuzumab Q3W |
| 58781000210100 |
BR NON-Metastatic - FEC-D100 [fluorouracil, epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel] |
| 58771000210102 |
BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] Q3W |
| 58761000210108 |
BR NON-Metastatic - zoledronic acid |
| 58751000210105 |
BR NON-Metastatic - neratinib |
| 58741000210107 |
BR NON-Metastatic - TCH [DOCEtaxel, cARBOplatin and trastuzumab] |
| 58731000210104 |
BR NON-Metastatic - PACLItaxel Q1W |
| 58721000210101 |
BR NON-Metastatic - Kadcyla [trastuzumab emtansine] |
| 58711000210106 |
BR NON-Metastatic - TCy [DOCEtaxel and CYCLOPHOSPHamide] |
| 58701000210109 |
BR Metastatic - zoledronic acid Q4W |
| 58691000210109 |
BR NON-Metastatic - cARBOplatin Q3W and PACLItaxel Q1W |
| 58681000210107 |
BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by PACLItaxel Q1W and trastuzumab Q3W |
| 58671000210105 |
BR Metastatic - capecitabine 1250 |
| 58661000210104 |
BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by DOCEtaxel Q3W |
| 58651000210102 |
BR Metastatic - trastuzumab Q3W |
| 58641000210100 |
BR Metastatic - DOXOrubicin Q3W |
| 58631000210108 |
BR Metastatic - eribulin |
| 58621000210106 |
BR Metastatic - PACLItaxel Q1W, pERTUZumab and trastuzumab Q3W |
| 58611000210101 |
BR Metastatic - DOXOrubicin Q1W |
| 58601000210103 |
BR Metastatic - cARBOplatin [5 AUC] and gemcitabine |
| 58591000210108 |
BR Metastatic - gemcitabine |
| 58581000210106 |
BR Metastatic - PACLItaxel Q1W and trastuzumab Q3W |
| 58571000210109 |
BR Metastatic - pamidronate |
| 58561000210103 |
BR Metastatic - goserelin Q12W |
| 58551000210101 |
BR Metastatic - pembrolizumab Q3W [flat dosing] |
| 58541000210104 |
BR Metastatic - fulvestrant |
| 58531000210107 |
BR Metastatic - denosumab |
| 58521000210105 |
BR Metastatic - MMM [mitomycin, mitoxantrone and metHOTREXATe] |
| 58511000210100 |
BR Metastatic - Kadcyla [trastuzumab emtansine] |
| 58501000210102 |
BR Metastatic - PACLItaxel Q1W |
| 58491000210107 |
BR Metastatic - everolimus and exemestane |
| 58481000210105 |
BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] and aTEZOLIzumab |
| 58471000210108 |
BR Metastatic - trastuzumab Q3W and vinORELBine [oral] |
| 58461000210102 |
BR Metastatic - trastuzumab Q3W and vinORELBine [IV] |
| 57851000210102 |
BR NON-Metastatic - PACLItaxel Q1W, pERTUZumab and trastuzumab Q3W |
| 57841000210100 |
BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W |
| 57831000210108 |
BR Metastatic - trastuzumab subcutaneous |
| 57821000210106 |
BR Metastatic - vinORELBine [IV] |
| 57811000210101 |
BR Metastatic - palbociclib |
| 57801000210103 |
BR Metastatic - goserelin Q4W |
| 57791000210102 |
BR Metastatic - cARBOplatin |
| 57781000210104 |
BR Metastatic - EC [epirubicin and CYCLOPHOSPHamide] |
| 57771000210101 |
BR Metastatic - vinORELBine [IV] Q1W |
| 57761000210107 |
BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] dose dense |
| 57751000210109 |
UGI PANC NON-Metastatic - capecitabine and gemcitabine [advanced] |
| 57741000210106 |
UGI PANC NON-Metastatic - capecitabine and gemcitabine [adjuvant] |
| 57731000210103 |
UGI PANC NON-Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid] |
| 57721000210100 |
UGI PANC Metastatic - PDXG [DOCEtaxel, gemcitabine, ciSplatin and capecitabine] |
| 57711000210105 |
UGI PANC NON-Metastatic - gemcitabine [adjuvant] |
| 57701000210108 |
UGI PANC Metastatic - olaparib |
| 57691000210108 |
UGI PANC NON-Metastatic - gemcitabine [advanced] |
| 57681000210106 |
UGI PANC NON-Metastatic - capecitabine chemoradiation [continuous dosing] |
| 57671000210109 |
UGI PANC NON-Metastatic - capecitabine chemoradiation [5 day dosing] |
| 57661000210103 |
SKIN SQCC Metastatic - pembrolizumab Q6W [flat dosing] |
| 57651000210101 |
SKIN SQCC Metastatic - pembrolizumab Q3W [weight based dosing] |
| 57641000210104 |
SKIN SQCC Metastatic - pembrolizumab Q3W [flat dosing] |
| 57631000210107 |
SKIN Melanoma NON-Metastatic - pembrolizumab Q6W [flat dosing] |
| 57621000210105 |
SKIN Melanoma NON-Metastatic - pembrolizumab Q3W [weight based dosing] |
| 57611000210100 |
SKIN Melanoma NON-Metastatic - pembrolizumab Q3W [flat dosing] |
| 57601000210102 |
SKIN Melanoma NON-Metastatic - nivolumab Q4W [flat dosing] |
| 57591000210107 |
SKIN Melanoma NON-Metastatic - nivolumab Q2W [weight based dosing] |
| 57581000210105 |
SKIN Melanoma NON-Metastatic - nivolumab Q2W [flat dosing] |
| 57571000210108 |
SKIN Melanoma Metastatic - pembrolizumab Q6W [flat dosing] |
| 57561000210102 |
SKIN Melanoma Metastatic - pembrolizumab Q3W [weight based dosing] |
| 57551000210100 |
SKIN Melanoma Metastatic - pembrolizumab Q3W [flat dosing] |
| 57541000210103 |
SKIN Melanoma Metastatic - nivolumab Q4W [flat dosing] |
| 57531000210106 |
SKIN Melanoma Metastatic - nivolumab Q2W [weight based dosing] |
| 57521000210109 |
SKIN Melanoma Metastatic - nivolumab Q2W [flat dosing] |
| 57511000210104 |
SKIN Melanoma Metastatic - ipilimumab and pembrolizumab |
| 57501000210101 |
SKIN Melanoma Metastatic - ipilimumab 3mg/kg and nivolumab 1mg/kg |
| 57491000210106 |
SKIN Melanoma Metastatic - ipilimumab 1mg/kg and nivolumab 3mg/kg |
| 57481000210109 |
SKIN Melanoma Metastatic - imatinib |
| 57471000210107 |
SKIN Melanoma Metastatic - dacarbazine |
| 57461000210101 |
SKIN Melanoma Metastatic - cOBIMEtinib and vemurafenib |
| 57451000210104 |
SKIN Melanoma Metastatic - cARBOplatin, PACLItaxel, and beVACizumab |
| 57441000210102 |
SKIN BCC Metastatic - vismodegib |
| 57431000210105 |
SKIN MCC Metastatic - pembrolizumab Q3W [flat dosing] |
| 57421000210108 |
SKIN MCC Metastatic - pembrolizumab Q3W [weight based dosing] |
| 57411000210103 |
SKIN MCC Metastatic - pembrolizumab Q6W [flat dosing] |
| 57401000210100 |
SKIN Melanoma Metastatic - biNIMEtinib and encorafenib |
| 57391000210103 |
LUNG SCLC NON-Metastatic - [Limited] cISplatin and etoposide |
| 57381000210100 |
LUNG SCLC NON-Metastatic - [Limited] cARBOplatin and etoposide |
| 57371000210102 |
LUNG SCLC Metastatic - CAV [Extensive] [CYCLOPHOSPHamide 750, DOXOrubicin and vinCRISTine] |
| 57361000210108 |
UGI HEP Metastatic - leNVAtinib |
| 57351000210105 |
UGI HEP Metastatic - aTEZOLIzumab and beVACizumab |
| 57341000210107 |
UGI HEP Metastatic - aTEZOLIzumab |
| 57331000210104 |
UGI GIST NON-Metastatic - imatinib |
| 57321000210101 |
UGI GIST Metastatic - sUNITinib [4/2 dosing] |
| 57311000210106 |
UGI GAST Metastatic - cISplatin, capecitabine and pembrolizumab [flat dose] |
| 57301000210109 |
UGI GAST AND OES Metastatic - cISplatin, fluorouracil and trastuzumab |
| 57291000210105 |
UGI GAST AND OES Metastatic - cISplatin, capecitabine and trastuzumab |
| 57281000210108 |
UGI BIL AND GBC NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 57271000210106 |
UGI PANC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] |
| 57261000210100 |
UGI PANC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 54251000210109 |
UGI GAST AND OES Metastatic - cISplatin and fluorouracil |
| 54241000210106 |
UGI OES NON-Metastatic - cISplatin and fluorouracil chemoradiation |
| 54231000210103 |
UGI BIL AND GBC Metastatic - cARBOplatin and gemcitabine |
| 54221000210100 |
UGI BIL AND GBC Metastatic - gemcitabine |
| 54211000210105 |
UGI BIL AND GBC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] |
| 54201000210108 |
UGI GAST AND OES Metastatic - trifluridine/tipiracil |
| 54191000210106 |
UGI BIL AND GBC NON-Metastatic - capecitabine |
| 54181000210109 |
UGI BIL AND GBC NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] |
| 54171000210107 |
UGI PANC Metastatic - gemcitabine |
| 54161000210101 |
UGI GIST Metastatic - sUNITinib [2/1 dosing] |
| 54151000210104 |
UGI BIL AND GBC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 54131000210105 |
UGI HEP Metastatic - soRAFENib |
| 54121000210108 |
UGI GAST AND OES Metastatic - cISplatin and capecitabine |
| 54111000210103 |
UGI GAST AND OES Metastatic - pembrolizumab Q3W [weight based dosing] |
| 54101000210100 |
UGI GAST AND OES Metastatic - raMUCIRumab |
| 54091000210107 |
UGI GAST AND OES Metastatic - PACLItaxel and raMUCIRumab |
| 54081000210105 |
UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 54071000210108 |
UGI GAST NON-Metastatic - fluorouracil chemoradiation [modified MacDonald] |
| 54061000210102 |
UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid] |
| 53971000210106 |
UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] and trastuzumab |
| 53071000210105 |
UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 53061000210104 |
UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin] |
| 53051000210102 |
UGI GAST AND OES NON-Metastatic - FLOT [DOCEtaxel, oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] |
| 53041000210100 |
UGI GIST Metastatic - imatinib |
| 53031000210108 |
UGI GAST AND OES NON-Metastatic - FLOT [DOCEtaxel, oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] |
| 53021000210106 |
UGI OES NON-Metastatic - mitomycin and fluorouracil chemoradiation [MSKCC] |
| 53011000210101 |
UGI OES NON-Metastatic - mitomycin and fluorouracil chemoradiation |
| 53001000210103 |
UGI OES NON-Metastatic - cISplatin and fluorouracil chemoradiation [Herskovic] |
| 52991000210102 |
UGI GIST Metastatic - regorafenib |
| 52981000210104 |
UGI GAST AND OES NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] chemoradiation [low dose foliNIc acid] |
| 52971000210101 |
UGI GAST AND OES Metastatic - pembrolizumab Q3W [flat dosing] |
| 52961000210107 |
UGI GAST NON-Metastatic - CAPOX [capecitabine and oxaliplatin] |
| 52951000210109 |
UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] and trastuzumab |
| 52941000210106 |
UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin] and trastuzumab |
| 52931000210103 |
UGI GAST AND OES NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] chemoradiation [high dose foliNIc acid] |
| 52921000210100 |
UGI GAST AND OES Metastatic - irinotecan Q2W |
| 52911000210105 |
UGI GAST AND OES Metastatic - PACLItaxel weekly [3/1 dosing] |
| 52901000210108 |
UGI GAST AND OES Metastatic - PACLItaxel weekly [continuous dosing] |
| 52891000210107 |
UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] |
| 52881000210105 |
UGI OES NON-Metastatic - cARBOplatin and PACLItaxel Q1W chemoradiation |
| 52871000210108 |
LUNG SCLC Metastatic - CAV [Extensive] [CYCLOPHOSPHamide 1000, DOXOrubicin and vinCRISTine] |
| 52861000210102 |
LUNG NSCLC NON-Metastatic - crizotinib |
| 52851000210100 |
LUNG NSCLC NON-Metastatic - cISplatin and etoposide chemoradiation |
| 52841000210103 |
LUNG NSCLC NON-Metastatic - [Superior sulcus Pancoast] cISplatin and etoposide chemoradiation |
| 52831000210106 |
LUNG NSCLC Metastatic - cARBOplatin and DOCEtaxel |
| 52821000210109 |
LUNG NSCLC Metastatic - cARBOplatin and pemetrexed |
| 52811000210104 |
LUNG NSCLC Metastatic - DOCEtaxel Q3W |
| 52801000210101 |
LUNG NSCLC Metastatic - DOCEtaxel Q1W |
| 52791000210100 |
CRC REC Metastatic - capecitabine chemoradiation [continuous dosing] |
| 52781000210102 |
LUNG NSCLC NON-Metastatic - durvalumab |
| 52771000210104 |
LUNG NSCLC NON-Metastatic - aTEZOLIzumab |
| 52761000210105 |
LUNG NSCLC Metastatic - nivolumab Q4W [flat dosing] |
| 52751000210107 |
LUNG NSCLC Metastatic - nivolumab Q2W [weight based dosing] |
| 52741000210109 |
LUNG NSCLC Metastatic - daBRAFEnib and tRAMEtinib |
| 52731000210101 |
LUNG NSCLC Metastatic - aTEZOLIzumab |
| 52721000210103 |
LUNG NSCLC Metastatic - aFATinib |
| 52711000210108 |
LUNG MESO Metastatic - cISplatin and pemetrexed |
| 52701000210106 |
LUNG NSCLC Metastatic - nivolumab Q2W [flat dosing] |
| 52691000210106 |
LUNG MESO Metastatic - cARBOplatin and pemetrexed |
| 52681000210109 |
LUNG NSCLC Metastatic - PACLItaxel Q1W |
| 52671000210107 |
LUNG NSCLC Metastatic - cARBOplatin, pemetrexed and pembrolizumab |
| 52661000210101 |
LUNG NSCLC Metastatic - crizotinib |
| 52651000210104 |
LUNG NSCLC Metastatic - cARBOplatin, PACLItaxel and pembrolizumab |
| 52641000210102 |
LUNG NSCLC Metastatic - cARBOplatin, PACLItaxel, aTEZOLIzumab and beVACizumab |
| 52631000210105 |
CRC REC Metastatic - capecitabine chemoradiation [5 day dosing] |
| 52621000210108 |
CRC Adjuvant - mRoswell Park [low dose foliNIc acid] |
| 52611000210103 |
CRC Metastatic - mDe Gramont [low dose foliNIc acid] |
| 52601000210100 |
CRC REC Metastatic - fluorouracil chemoradiation |
| 52591000210105 |
CRC Metastatic - mDe Gramont [high dose foliNIc acid] |
| 52581000210108 |
BR Metastatic - capecitabine 1000 |
| 52571000210106 |
LUNG MESO Metastatic - vinORELBine |
| 52561000210100 |
GU PROS Castration resistant Metastatic - cARBOplatin and DOCEtaxel |
| 52551000210103 |
LUNG NSCLC Metastatic - cARBOplatin and Q1W PACLItaxel |
| 52541000210101 |
GU PROS Metastatic - zoledronic acid Q12W |
| 52531000210109 |
GU PROS Castration resistant Metastatic - enzalutamide |
| 52521000210107 |
GU PROS Metastatic - zoledronic acid Q4W |
| 52511000210102 |
GU PROS Castration resistant Metastatic - cabazitaxel Q3W and prEDNISone |
| 52501000210104 |
CRC Metastatic - raltitrexed and oxaliplatin |
| 52491000210109 |
CRC Adjuvant - mRoswell Park [high dose foliNIc acid] |
| 52481000210107 |
CRC Metastatic - mRoswell Park [low dose foliNIc acid] |
| 52471000210105 |
CRC Metastatic - raltitrexed |
| 52461000210104 |
GU PROS Metastatic - goserelin |
| 52451000210102 |
GU PROS Castration resistant Metastatic - abiraterone and dexamethasone |
| 52441000210100 |
GU PROS Castration resistant NON-Metastatic - apalutamide |
| 52431000210108 |
GU PROS Castration sensitive Metastatic - apalutamide |
| 52421000210106 |
GU PROS Metastatic - bicalutamide |
| 52411000210101 |
GU PROS Metastatic - flutamide |
| 52401000210103 |
LUNG NSCLC NON-Metastatic - alectinib |
| 52391000210101 |
GU PROS Castration resistant Metastatic - DOCEtaxel Q2W and prEDNISone |
| 52381000210103 |
GU PROS Castration resistant Metastatic - DOCEtaxel Q3W and prEDNISone |
| 52371000210100 |
GU PROS Castration sensitive Metastatic - abiraterone and prEDNISone |
| 52361000210106 |
GU PROS Castration sensitive Metastatic - DOCEtaxel Q3W |
| 52351000210108 |
GU PROS Metastatic - cyproterone |
| 52341000210105 |
GU PROS Metastatic - pembrolizumab [flat dose] |
| 52331000210102 |
LUNG NSCLC Advanced/Metastatic - alectinib |
| 52321000210104 |
GU PROS Castration resistant Metastatic - abiraterone and prEDNISone |
| 52311000210109 |
GU PROS Castration resistant Metastatic - abiraterone and prEDNISone [fed state] |
| 52301000210107 |
CRC Metastatic - mFOLFOXIRI with beVACizumab [high dose foliNIc acid] |
| 52291000210108 |
CRC Metastatic - mFOLFIRI and CETUximab [Q1W] [high dose foliNIc acid] |
| 52281000210106 |
CRC Metastatic - mFOLFIRI and CETUximab [Q1W] [low dose foliNIc acid] |
| 52271000210109 |
CRC Metastatic - mFOLFOXIRI [high dose foliNIc acid] |
| 52261000210103 |
CRC Metastatic - mFOLFOXIRI [low dose foliNIc acid] |
| 52251000210101 |
CRC Metastatic - mFOLFOXIRI with beVACizumab [low dose foliNIc acid] |
| 52241000210104 |
CRC Metastatic - mRoswell Park [high dose foliNIc acid] |
| 52231000210107 |
CRC REC Locally advanced - fluorouracil chemoradiation |
| 52221000210105 |
CRC REC Locally advanced - capecitabine chemoradiation [continuous dosing] |
| 52211000210100 |
CRC REC Locally advanced - capecitabine chemoradiation [5 day dosing] |
| 52201000210102 |
CRC Adjuvant - mFOLFOX6 [low dose foliNIc acid] |
| 52191000210104 |
CRC Adjuvant - mFOLFOX6 [high dose foliNIc acid] |
| 52181000210101 |
CRC Adjuvant - CAPOX |
| 52171000210103 |
CRC Adjuvant - capecitabine |
| 52161000210109 |
CRC Metastatic - regorafenib |
| 52151000210106 |
CRC Metastatic - mFOLFOX6 and CETUximab [Q2W] [low dose foliNIc acid] |
| 52141000210108 |
CRC Metastatic - mFOLFOX6 and CETUximab [Q2W] [high dose foliNIc acid] |
| 52131000210100 |
CRC Metastatic - mFOLFOX6 and beVACizumab [low dose foliNIc acid] |
| 52121000210102 |
CRC Metastatic - mFOLFOX6 and beVACizumab [high dose foliNIc acid] |
| 52111000210107 |
CRC Metastatic - mFOLFOX6 [low dose foliNIc acid] |
| 52101000210105 |
CRC Metastatic - mFOLFOX6 [high dose foliNIc acid] |
| 52091000210103 |
CRC Metastatic - mFOLFIRI and CETUximab [Q2W] [low dose foliNIc acid] |
| 52081000210100 |
CRC Metastatic - CAPOX |
| 52071000210102 |
CRC Metastatic - capecitabine 1000 |
| 52061000210108 |
CRC Metastatic - capecitabine 1250 |
| 52051000210105 |
CRC Metastatic - capecitabine and beVACizumab |
| 52041000210107 |
CRC Metastatic - capecitabine and mitomycin |
| 52031000210104 |
CRC Metastatic - CAPOX and beVACizumab |
| 52021000210101 |
CRC Metastatic - CETUximab [Q1W] |
| 52011000210106 |
CRC Metastatic - CETUximab [Q1W] and irinotecan [Q2W] |
| 52001000210109 |
CRC Metastatic - CETUximab and irinotecan [Q2W] |
| 51991000210106 |
CRC Metastatic - irinotecan Q3W |
| 51981000210109 |
CRC Metastatic - IrOX |
| 51971000210107 |
CRC Metastatic - mCAPIRI |
| 51961000210101 |
CRC Metastatic - mFOLFIRI [high dose foliNIc acid] |
| 51951000210104 |
CRC Metastatic - mFOLFIRI [low dose foliNIc acid] |
| 51941000210102 |
CRC Metastatic - mFOLFIRI and beVACizumab [high dose foliNIc acid] |
| 51931000210105 |
CRC Metastatic - mFOLFIRI and beVACizumab [low dose foliNIc acid] |
| 51921000210108 |
CRC Metastatic - mFOLFIRI and CETUximab [Q2W] [high dose foliNIc acid] |
| 51911000210103 |
CRC Metastatic - FLOX |
| 51901000210100 |
CRC Adjuvant - mQUASAR |
| 51891000210101 |
CRC Adjuvant - MAYO |
| 51881000210103 |
CRC Metastatic - mQUASAR |
| 467351000210109 |
Both sides |
| 467491000210105 |
Completed |
| 467501000210100 |
Failed |
| 455881000210107 |
Can be assessed |
| 455891000210109 |
Cannot be assessed |
| 392231000210101 |
New primary tumour |
| 392241000210109 |
Local recurrence tumour |
| 392261000210105 |
Distant metastasis tumour |
| 381081000210101 |
National screening programme |
| 448111000210100 |
Primary non cutaneous malignant melanoma (disorder) |
| 298161000210105 |
Other thoracic primary |
| 93880001 |
Other lung primary |
| 476101000210102 |
Nasal primary |
| 476471000210102 |
Molar pregnancy |
| 476481000210100 |
Uterine primary |
| 476511000210105 |
Testicular seminoma primary |
| 476521000210100 |
Testicular non-seminoma primary |
| 476501000210108 |
Testicular other primary |
| 93885006 |
Other male genital primary |
| 94125001 |
Other urinary system primary |
| 297911000210105 |
Other gynaecological primary |
| 93725000 |
Other bone primary |
| 372010005 |
Other soft tissue primary |
| 93744007 |
Other CNS primary |
| 476561000210107 |
Neoadjuvant radiotherapy |
| 476571000210101 |
Neoadjuvant hormone therapy |
